Unknown

Dataset Information

0

ERCC1 rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations.


ABSTRACT: Background:A number of studies have investigated the roles of excision repair cross-complementation group 1 (ERCC1) gene rs3212986 polymorphisms as potential biomarkers in gastric cancer (GC). However, the results were inconsistent. Here, we performed a meta-analysis to explore ERCC1 rs3212986 polymorphisms in the chemotherapy response and clinical outcome of GC. Methods:PubMed, Embase, and Web of Science were searched up to July 28, 2017, for studies on the association between ERCC1 rs3212986 A/C polymorphisms and response to chemotherapy as well as overall survival time of GC. A fixed-effect or random-effect model was used to calculate the pooled odds ratios (ORs) based on the results from the heterogeneity tests. Results:The result revealed that there was no significant association between the ERCC1 rs3212986 A/C polymorphism and response to chemotherapy in GC under comparison models (AA + CA versus CC, OR 0.95, P=0.80, AA versus CA, OR 0.85, P=0.55, AA versus CC, OR 0.74, P=0.47). Further identification suggested that ERCC1 rs3212986 A/C polymorphisms were not linked with the overall survival of GC (AA + CA versus CC, OR 1.09, P=0.52, AA versus CA, OR 1.05, P=0.85, AA versus CC, OR 1.43, P=0.23). Conclusion:Our meta-analysis indicated that the ERCC1 rs3212986 A/C polymorphism was not associated with response to chemotherapy or overall survival time in GC. Well-designed studies with larger sample sizes and more ethnic groups should be performed to further validate our results.

SUBMITTER: Tang W 

PROVIDER: S-EPMC5741989 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

<i>ERCC1</i> rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations.

Tang Weiwei W   Wang Hanjin H   Wang Yuemei Y   Wang Xiaowei X  

OncoTargets and therapy 20171220


<h4>Background</h4>A number of studies have investigated the roles of excision repair cross-complementation group 1 (<i>ERCC1</i>) gene rs3212986 polymorphisms as potential biomarkers in gastric cancer (GC). However, the results were inconsistent. Here, we performed a meta-analysis to explore <i>ERCC1</i> rs3212986 polymorphisms in the chemotherapy response and clinical outcome of GC.<h4>Methods</h4>PubMed, Embase, and Web of Science were searched up to July 28, 2017, for studies on the associat  ...[more]

Similar Datasets

| S-EPMC6308093 | biostudies-literature
| S-EPMC4320740 | biostudies-literature
| S-EPMC9568358 | biostudies-literature
| S-EPMC3509400 | biostudies-literature
| S-EPMC9878395 | biostudies-literature
| S-EPMC5581134 | biostudies-literature
| S-EPMC5474010 | biostudies-literature
| S-EPMC9639052 | biostudies-literature
| S-EPMC4139873 | biostudies-literature
| S-EPMC10094077 | biostudies-literature